ProQR Therapeutics NV Company Profile (NASDAQ:PRQR)

About ProQR Therapeutics NV

ProQR Therapeutics NV logoProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber's congenital amaurosis (LCA). It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010 and QR-110. It is focusing on developing QRX- 911, QRX- 021, QRX- 313, QRX- 704, QRX- 812, QRX- 411, QRX- 504, QRX- 604 and QRX- 203. QR-010 is an RNA-based oligonucleotide. QR-110, is an oligonucleotide.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PRQR
  • CUSIP:
Key Metrics:
  • Previous Close: $4.00
  • 50 Day Moving Average: $4.18
  • 200 Day Moving Average: $5.12
  • 52-Week Range: $3.55 - $8.70
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.08
  • P/E Growth: 0.00
  • Market Cap: $94.55M
  • Outstanding Shares: 23,346,000
  • Beta: 0.87
Profitability:
  • Return on Equity: -48.21%
  • Return on Assets: -41.85%
Debt:
  • Debt-to-Equity Ratio: 0.06%
  • Current Ratio: 8.90%
  • Quick Ratio: 8.90%
Additional Links:
Companies Related to ProQR Therapeutics NV:

Analyst Ratings

Consensus Ratings for ProQR Therapeutics NV (NASDAQ:PRQR) (?)
Ratings Breakdown: 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $15.90 (292.59% upside)

Analysts' Ratings History for ProQR Therapeutics NV (NASDAQ:PRQR)
Show:
DateFirmActionRatingPrice TargetDetails
10/31/2016Chardan CapitalReiterated RatingHold$4.50View Rating Details
10/30/2016HC WainwrightSet Price TargetBuy$40.00View Rating Details
10/14/2016Leerink SwannReiterated RatingOutperform$14.00View Rating Details
9/28/2016Janney Montgomery ScottInitiated CoverageNeutral$7.00View Rating Details
9/6/2016JMP SecuritiesReiterated RatingBuyView Rating Details
(Data available from 3/1/2015 forward)

Earnings

Earnings History for ProQR Therapeutics NV (NASDAQ:PRQR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/17/2017        
5/18/2016Q1($0.41)($0.50)ViewN/AView Earnings Details
2/17/2016Q4($0.35)($0.29)ViewN/AView Earnings Details
11/23/2015Q3($0.36)($0.29)ViewN/AView Earnings Details
8/19/2015($0.32)($0.41)ViewN/AView Earnings Details
5/21/2015($0.29)$0.01ViewN/AView Earnings Details
2/26/2015($0.27)($0.30)ViewN/AView Earnings Details
11/24/2014($1.00)($0.53)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ProQR Therapeutics NV (NASDAQ:PRQR)
Current Year EPS Consensus Estimate: $-1.83 EPS
Next Year EPS Consensus Estimate: $-1.95 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.63)($0.63)($0.63)
Q4 20161($0.48)($0.48)($0.48)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ProQR Therapeutics NV (NASDAQ:PRQR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ProQR Therapeutics NV (NASDAQ:PRQR)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for ProQR Therapeutics NV (NASDAQ:PRQR)
DateHeadline
us.rd.yahoo.com logoProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update (NASDAQ:PRQR)
us.rd.yahoo.com - February 28 at 3:49 PM
finance.yahoo.com logoOn a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day (NASDAQ:PRQR)
finance.yahoo.com - February 27 at 9:44 AM
News IconProQR Therapeutics NV PRQR Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:PRQR)
www.bioportfolio.com - January 22 at 12:08 AM
finance.yahoo.com logoCan The Uptrend Continue for ProQR Therapeutics (PRQR)? (NASDAQ:PRQR)
finance.yahoo.com - December 29 at 8:58 AM
News IconHow ProQR Therapeutics NV (PRQR) Stacks Up Against Its Peers (NASDAQ:PRQR)
feedproxy.google.com - December 16 at 10:15 PM
capitalcube.com logoProQR Therapeutics NV :PRQR-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016 (NASDAQ:PRQR)
www.capitalcube.com - December 1 at 7:15 PM
publicnow.com logoProQR Announces Results for the Third Quarter of 2016 (NASDAQ:PRQR)
www.publicnow.com - November 18 at 10:13 AM
finance.yahoo.com logoBlog Coverage ProQR Cystic Fibrosis Drug Meets Primary End Point (NASDAQ:PRQR)
finance.yahoo.com - October 28 at 10:41 AM
News IconHere’s Our Take On The Latest ProQR Therapeutics NV (PRQR) Release (NASDAQ:PRQR)
feedproxy.google.com - October 27 at 1:37 PM
nasdaq.com logoMid-Morning Market Update: Markets Open Higher; Twitter Beats Q3 Expectations (NASDAQ:PRQR)
www.nasdaq.com - October 27 at 11:52 AM
stockhouse.com logoProQR Shares Spiking 40% (NASDAQ:PRQR)
www.stockhouse.com - October 27 at 11:52 AM
finance.yahoo.com logoProQR Therapeutics (PRQR) Worth a Look: Stock Up 9.8% (NASDAQ:PRQR)
finance.yahoo.com - October 27 at 11:52 AM
thestreet.com logoProQR Cystic Fibrosis Drug Passes First, Early Efficacy Test (NASDAQ:PRQR)
www.thestreet.com - October 27 at 11:52 AM
finance.yahoo.com logoProQR Jumps on Positive Phase 1 Results (NASDAQ:PRQR)
finance.yahoo.com - October 27 at 11:52 AM
finance.yahoo.com logoProQR Therapeutics N.V. (PRQR) is Overbought: Is A Drop Coming? (NASDAQ:PRQR)
finance.yahoo.com - September 27 at 6:45 PM
publicnow.com logoProQR Announces Clinical Data Presentations and Investor & Analyst Event at NACFC (NASDAQ:PRQR)
www.publicnow.com - September 27 at 11:27 AM
publicnow.com logoProQR to Present at Scientific and Investor Conferences in September (NASDAQ:PRQR)
www.publicnow.com - September 6 at 11:39 AM
publicnow.com logoProQR Announces Results for the Second Quarter of 2016 (NASDAQ:PRQR)
www.publicnow.com - August 17 at 9:56 AM
finance.yahoo.com logoProQR Receives Fast Track Designation from FDA for QR-010 for Cystic Fibrosis (NASDAQ:PRQR)
finance.yahoo.com - July 19 at 7:00 AM
publicnow.com logoProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC (NASDAQ:PRQR)
www.publicnow.com - June 21 at 9:19 AM
finance.yahoo.com logoCoverage initiated on ProQR Therapeutics by Chardan Capital Markets (NASDAQ:PRQR)
finance.yahoo.com - June 20 at 5:50 AM
capitalcube.com logoProQR Therapeutics NV :PRQR-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 (NASDAQ:PRQR)
www.capitalcube.com - June 8 at 6:03 PM
publicnow.com logoProQR Announces Presentations at the European CF Conference and the JMP Life Science Conference (NASDAQ:PRQR)
www.publicnow.com - June 1 at 7:23 AM
publicnow.com logoProQR’s Drug Candidate QR-110 for Leber’s Congenital Amaurosis Type 10 Receives EMA and FDA Orphan Drug Designation (NASDAQ:PRQR)
www.publicnow.com - June 1 at 7:23 AM
finance.yahoo.com logo7:04 am ProQR Therapeutics confirms that its investigational drug QR-110 has received orphan drug designation from both the FDA and the EMA for the treatment of Leber's congenital amaurosis Type 10 (NASDAQ:PRQR)
finance.yahoo.com - June 1 at 7:04 AM
publicnow.com logoProQR Announces Results for the First Quarter of 2016 (NASDAQ:PRQR)
www.publicnow.com - May 18 at 7:42 AM
sg.finance.yahoo.com logoProQR reports 1Q loss (NASDAQ:PRQR)
sg.finance.yahoo.com - May 18 at 7:23 AM
sg.finance.yahoo.com logoProQR reports 4Q loss (NASDAQ:PRQR)
sg.finance.yahoo.com - February 17 at 7:19 AM
finance.yahoo.com logoProQR to Present at the Leerink Partners Global Healthcare Conference (NASDAQ:PRQR)
finance.yahoo.com - February 3 at 7:00 AM
finance.yahoo.com logoWhy ProQR Therapeutics (PRQR) Stock Might be a Great Pick (NASDAQ:PRQR)
finance.yahoo.com - December 22 at 8:33 AM
insidermonkey.com logoHedge Funds Aren’t Crazy About ProQR Therapeutics NV (PRQR) Anymore (NASDAQ:PRQR)
www.insidermonkey.com - December 14 at 9:24 PM
finance.yahoo.com logoProQR Therapeutics (PRQR) Rises: Stock Up 6.1% in Session (NASDAQ:PRQR)
finance.yahoo.com - December 9 at 8:45 AM
finance.yahoo.com logoPROQR THERAPEUTICS N.V. Financials (NASDAQ:PRQR)
finance.yahoo.com - December 8 at 1:09 PM
finance.yahoo.com logoProQR Announces R&D Day and Provides Update on Innovation Portfolio (NASDAQ:PRQR)
finance.yahoo.com - November 30 at 7:00 AM
finance.yahoo.com logoProQR Therapeutics (PRQR) Falls: Stock Goes Down 24.8% (NASDAQ:PRQR)
finance.yahoo.com - November 24 at 8:50 AM
noodls.com logoProQR Announces Results for the Third Quarter of 2015 and Provides Update on Clinical Trials (NASDAQ:PRQR)
www.noodls.com - November 23 at 7:02 AM
sg.finance.yahoo.com logoProQR reports 3Q loss (NASDAQ:PRQR)
sg.finance.yahoo.com - November 23 at 6:39 AM
noodls.com logoProQR Announces an Investor and Analyst Event and Pre-Clinical Data Presentations for QR-010 for Cystic Fibrosis at Two Upcoming Scientific Conferences (NASDAQ:PRQR)
www.noodls.com - October 1 at 7:18 AM
noodls.com logoProQR Announces a Proof-of-Concept Nasal Potential Difference Study of QR-010 is Open for Enrollment (NASDAQ:PRQR)
www.noodls.com - September 14 at 7:15 AM
noodls.com logoProQR Announces Results for the Second Quarter of 2015 (NASDAQ:PRQR)
www.noodls.com - August 19 at 8:38 AM
sg.finance.yahoo.com logoProQR reports 2Q loss (NASDAQ:PRQR)
sg.finance.yahoo.com - August 19 at 8:15 AM

Social

What is ProQR Therapeutics NV's stock symbol?

ProQR Therapeutics NV trades on the NASDAQ under the ticker symbol "PRQR."

Where is ProQR Therapeutics NV's stock going? Where will ProQR Therapeutics NV's stock price be in 2017?

5 equities research analysts have issued 1 year target prices for ProQR Therapeutics NV's stock. Their forecasts range from $4.50 to $40.00. On average, they expect ProQR Therapeutics NV's stock price to reach $15.90 in the next year.

When will ProQR Therapeutics NV announce their earnings?

ProQR Therapeutics NV is scheduled to release their next quarterly earnings announcement on Friday, February, 17th 2017.

Who owns ProQR Therapeutics NV stock?

ProQR Therapeutics NV's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Orbimed Advisors LLC (9.88%), Janus Capital Management LLC (1.69%), Franklin Resources Inc. (1.33%) and FMR LLC (1.02%).

Who sold ProQR Therapeutics NV stock? Who is selling ProQR Therapeutics NV stock?

ProQR Therapeutics NV's stock was sold by a variety of institutional investors in the last quarter, including Janus Capital Management LLC.

How do I buy ProQR Therapeutics NV stock?

Shares of ProQR Therapeutics NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of ProQR Therapeutics NV stock cost?

One share of ProQR Therapeutics NV stock can currently be purchased for approximately $4.05.

ProQR Therapeutics NV (NASDAQ:PRQR) Chart for Wednesday, March, 1, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for ProQR Therapeutics NV (NASDAQ:PRQR)

Earnings History Chart

Earnings by Quarter for ProQR Therapeutics NV (NASDAQ:PRQR)

Dividend History Chart

Dividend Payments by Quarter for ProQR Therapeutics NV (NASDAQ:PRQR)

Last Updated on 3/1/2017 by MarketBeat.com Staff